Day: January 9, 2026

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds. The Company intends to use the net proceeds from the Offering to fund future clinical trials for the Company’s drug candidates, including for absence seizures, DEE, and Prader-Willi Syndrome,...

Hauppauge, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) —  Cemtrex, Inc. (NASDAQ: CETX) (the “Company”), an advanced security technology and industrial services company, today announced that it has entered into a definitive agreement for the purchase of approximately 1,469,507 shares and / or pre funded warrants with a single institutional investor, at a purchase price of $2.722 per share, with gross proceeds to the Company expected to be $4 million to the Company. The transaction is expected to close on or about January 9, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, for general corporate purposes, including working capital and potential acquisitions. The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-283995)...

DURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, January 13, 2026, at the J.P. Morgan Annual Healthcare Conference (San Francisco). CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the conference. The live webcast and replay can be accessed through the “Events” section of Fortrea’s  Investor Relations website. Investors interested in one-on-one meetings should contact their banking representatives. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies...

Westwood One, Official Network Audio Partner of the NFL, Delivers All the Action with Live Play-by-Play Coverage of All Six NFL Games on Saturday, January 10, Sunday, January 11, and Monday, January 12NFL LogoNFL LogoNEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) — Cumulus Media’s (OTCQB:CMLS) Westwood One, the official network audio partner of the National Football League, will present live play-by-play coverage of NFL Wild Card Weekend, powered by Verizon, on Saturday, January 10, Sunday, January 11, and Monday, January 12. This season marks Westwood One’s 39th consecutive year as the exclusive network audio partner of the NFL. Westwood One opens NFL Wild Card Weekend on Saturday, January 10, with live coverage of the match-up between the Los Angeles Rams and the Carolina Panthers in Charlotte at 4:00pm ET, followed by the...

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT manufacturing network alongside existing Indiana, New Jersey, and recently completed California sitesNovartis RLT portfolio advancing with new isotopes, ligands and combination therapies, bringing innovation to new cancer typesEast Hanover, N.J., January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company’s $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet...

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT manufacturing network alongside existing Indiana, New Jersey, and recently completed California sitesNovartis RLT portfolio advancing with new isotopes, ligands and combination therapies, bringing innovation to new cancer typesBasel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company’s $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand...

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®,” said Craig Collard, Chief Executive Officer of Heron. “In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year.” Preliminary Fourth Quarter and Full Year 2025 UpdatesNet revenue of approximately $40.5 million for the three months ended December 31, 2025.ZYNRELEF® net revenue of approximately $12.5 million for the three months ended December 31, 2025. APONVIE®...

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) — Cabot Corporation (NYSE: CBT) today announced that it will release operating results for the first quarter of fiscal 2026 on Tuesday, February 3, 2026, after the market close. The Company will host a conference call and live webcast to review the first quarter results beginning at 8:00 am (ET) on Wednesday, February 4, 2026. The call will be webcast by Notified and may be accessed through Cabot’s website at https://cabotog.gcs-web.com/. If you are unable to participate during the live webcast, the call and accompanying slide presentation will be archived on the Company’s website at https://cabotog.gcs-web.com/. ABOUT CABOT CORPORATIONCabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company is a leading...

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) — Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Investment Memorandum”) with Future Biotechnology Group Co., Ltd (hereinafter referred to as “Future Biotechnology Group”). The Investment Memorandum outlines an initial investment of US$30 million to be paid in cash, as well as subsequent acquisitions with a consideration, in aggregate, of US$60 million to be settled in cash and share issuances (the “Consideration Shares”). The Consideration Shares are to be held escrow and released in accordance with performance targets over an evaluation period of 3 years from January 2026 to December 2028. Performance Targets January 1, 2026 – December 31, 2026:The target company shall achieve audited...